LON:MXCT - MaxCyte Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 848
▼ -2 (-0.24%)
1 month | 3 months | 12 months
Get New MaxCyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MXCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MXCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for MaxCyte in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 848.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in MaxCyte. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
9/19/2017Panmure GordonReiterated RatingBuyGBX 338
i
4/25/2017Panmure GordonLower Price TargetBuyGBX 349 ➝ GBX 338
i
3/20/2017Panmure GordonBoost Price TargetBuyGBX 280 ➝ GBX 349
i
2/22/2017Panmure GordonReiterated RatingBuyGBX 266
i
1/24/2017Panmure GordonBoost Price TargetBuyGBX 170 ➝ GBX 266
i
1/6/2017Panmure GordonReiterated RatingBuyGBX 170
i
12/21/2016Panmure GordonReiterated RatingBuyGBX 170
i
9/27/2016Panmure GordonReiterated RatingBuyGBX 170
i
9/20/2016Panmure GordonReiterated RatingBuyGBX 170
i
9/6/2016Panmure GordonReiterated RatingBuyGBX 170
i
7/12/2016Panmure GordonReiterated RatingBuyGBX 170
i
5/10/2016Panmure GordonReiterated RatingBuyGBX 170
i
(Data available from 4/21/2016 forward)
MaxCyte logo
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More

Today's Range

Now: GBX 848
840
870

50 Day Range

MA: GBX 883.38
844
990

52 Week Range

Now: GBX 848
140
1,060

Volume

13,627 shs

Average Volume

241,018 shs

Market Capitalization

£804.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of MaxCyte?

The following equities research analysts have issued research reports on MaxCyte in the last year:
View the latest analyst ratings for MXCT.

What is the current price target for MaxCyte?

0 Wall Street analysts have set twelve-month price targets for MaxCyte in the last year. has the lowest price target set, forecasting a price of £100,000 for MaxCyte in the next year.
View the latest price targets for MXCT.

What is the current consensus analyst rating for MaxCyte?

MaxCyte currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MXCT.

What other companies compete with MaxCyte?

How do I contact MaxCyte's investor relations team?

MaxCyte's physical mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company's listed phone number is +1-301-9441700. The official website for MaxCyte is www.maxcyte.com.